Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$0.27
-0.5%
$0.27
$0.20
$1.48
$73.10M2.181.63 million shs519,720 shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$10.85
-1.4%
$9.57
$2.20
$12.78
$301.29M-0.59190,421 shs2,593 shs
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$4.83
+2.1%
$4.83
$3.61
$11.09
$52.45M1.43225,325 shs173,043 shs
Rubius Therapeutics, Inc. stock logo
RUBY
Rubius Therapeutics
$0.06
$0.04
$0.00
$0.38
$5.16M2.591.15 million shs755,858 shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.35
+15.7%
$0.46
$0.26
$1.07
$79.22M1.142.65 million shs2.48 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-0.54%+9.28%-1.08%+23.39%-76.95%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-1.36%-5.97%+20.56%+48.22%+171.59%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
+2.11%+10.40%-7.12%+9.77%-50.41%
Rubius Therapeutics, Inc. stock logo
RUBY
Rubius Therapeutics
0.00%0.00%0.00%0.00%0.00%
Vaxart, Inc. stock logo
VXRT
Vaxart
+15.67%-19.68%-11.68%-2.58%-47.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.429 of 5 stars
3.15.00.00.02.10.80.0
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
3.6155 of 5 stars
4.43.00.00.01.92.50.6
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
4.5883 of 5 stars
3.53.00.04.63.01.71.3
Rubius Therapeutics, Inc. stock logo
RUBY
Rubius Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
2.5777 of 5 stars
3.51.00.00.03.41.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.29
Hold$1.35392.77% Upside
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.80
Moderate Buy$14.7535.94% Upside
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
3.00
Buy$47.00873.08% Upside
Rubius Therapeutics, Inc. stock logo
RUBY
Rubius Therapeutics
0.00
N/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
3.00
Buy$3.00764.55% Upside

Current Analyst Ratings Breakdown

Latest DTIL, DBVT, ADAP, RUBY, and VXRT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$1.50 ➝ $0.50
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$21.00
5/29/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell$7.25
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.00
5/21/2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
5/14/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.00
5/14/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.46
5/5/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $16.00
5/1/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $15.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$178.03M0.41N/AN/A$0.05 per share5.49
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$4.15M71.61N/AN/A$1.42 per share7.64
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$68.70M0.78N/AN/A$6.87 per share0.70
Rubius Therapeutics, Inc. stock logo
RUBY
Rubius Therapeutics
N/AN/AN/AN/A$0.17 per shareN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
$47.40M1.67N/AN/A$0.26 per share1.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$70.81M-$0.27N/AN/AN/A-38.91%-163.73%-23.65%8/11/2025 (Estimated)
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$113.92M-$4.92N/AN/AN/A-3,249.99%-278.24%-140.54%7/29/2025 (Estimated)
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%7/30/2025 (Estimated)
Rubius Therapeutics, Inc. stock logo
RUBY
Rubius Therapeutics
-$179.67MN/A0.00N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
-$66.95M-$0.27N/AN/AN/A-122.63%-91.89%-38.40%8/14/2025 (Estimated)

Latest DTIL, DBVT, ADAP, RUBY, and VXRT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$0.09N/AN/AN/AN/AN/A
7/29/2025Q2 2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$0.28N/AN/AN/A$0.64 millionN/A
5/15/2025Q1 2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million
5/13/2025Q1 2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million
5/13/2025Q1 2025
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.07-$0.07N/A-$0.07$2.85 million$20.88 million
4/11/2025Q4 2024
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A-$1.10N/A-$1.10N/A$0.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
N/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/AN/A
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
N/AN/AN/AN/AN/A
Rubius Therapeutics, Inc. stock logo
RUBY
Rubius Therapeutics
N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
4.24
2.02
1.79
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A
0.72
0.72
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
0.45
6.62
6.62
Rubius Therapeutics, Inc. stock logo
RUBY
Rubius Therapeutics
N/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
0.64
0.64

Institutional Ownership

CompanyInstitutional Ownership
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
31.37%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
71.74%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
37.99%
Rubius Therapeutics, Inc. stock logo
RUBY
Rubius Therapeutics
N/A
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
490265.05 million231.28 millionOptionable
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
8027.39 million27.00 millionOptionable
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
20011.09 million10.59 millionNo Data
Rubius Therapeutics, Inc. stock logo
RUBY
Rubius Therapeutics
690.48 million85.69 millionNot Optionable
Vaxart, Inc. stock logo
VXRT
Vaxart
120228.31 million222.37 millionOptionable

Recent News About These Companies

OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptimmune Therapeutics stock logo

Adaptimmune Therapeutics NASDAQ:ADAP

$0.27 0.00 (-0.54%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$0.27 -0.01 (-1.93%)
As of 04:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

DBV Technologies stock logo

DBV Technologies NASDAQ:DBVT

$10.85 -0.15 (-1.36%)
Closing price 07/10/2025 03:58 PM Eastern
Extended Trading
$11.21 +0.36 (+3.33%)
As of 05:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Precision BioSciences stock logo

Precision BioSciences NASDAQ:DTIL

$4.83 +0.10 (+2.11%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$4.78 -0.04 (-0.93%)
As of 04:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Rubius Therapeutics stock logo

Rubius Therapeutics NASDAQ:RUBY

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

Vaxart stock logo

Vaxart NASDAQ:VXRT

$0.35 +0.05 (+15.67%)
As of 07/10/2025 03:59 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.